ProKidney (PROK) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solid Biosciences (SLDB) has outperformed ProKidney (PROK) over the past year, gaining 8.1% versus a loss of 47.0%. Over five years, SLDB leads with a -79.8% price change compared with -84.1% for PROK. Solid Biosciences is the larger company by market cap ($731.3 million vs $662.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | SLDB |
|---|---|---|
| Share price | $1.66 | $6.82 |
| Market cap | $662.64M | $731.28M |
| 1-day change | +5.73% | -0.44% |
| YTD return | -29.91% | +20.92% |
| 1-year return | -46.96% | +8.08% |
| 5-year return | -84.09% | -79.79% |
| EPS (TTM) | $-0.55 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $11.45 |
| 52-week low | $1.30 | $3.79 |
| Distance from 52-week high | -52.30% | -40.44% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +276.51% | +173.02% |
| Average volume | 1.30M | 1.09M |
| Shares outstanding | 208.93M | 107.23M |
| Employees | 231 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed PROK by 55.0 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
PROK vs SLDB FAQ
Which is bigger, ProKidney or Solid Biosciences?
Solid Biosciences (SLDB) is larger, with a market capitalization of $731.28M compared with $662.64M for ProKidney (PROK).
Which stock has performed better over the past year, PROK or SLDB?
SLDB returned +8.08% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.